Business Context and Reporting Period
Company: Smith & Nephew plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: First Quarter ended March 29, 2025
Business Overview: A global medical technology business focused on Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company operates in approximately 100 countries with 17,000 employees.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 | Change |
|---|---|---|---|
| Consolidated Revenue | $1,407 million | $1,386 million | +1.6% (Reported) |
| Underlying Revenue Growth | +3.1% (Excluding FX and acquisitions/disposals) | ||
| Foreign Exchange Impact | -150 basis points headwind | ||
| Trading Profit Margin Guidance (FY 2025) | 19.0% to 20.0% (Expected expansion) | ||
| Tariff Impact (FY 2025) | Expected net impact of $15 to $20 million |
Note: The filing does not provide specific Q1 2025 profit, cash flow, or debt figures. It focuses on revenue performance and full-year margin guidance.
Material Changes vs. Prior Period
- Revenue Growth: Reported revenue increased 1.6% year-over-year, driven by operational improvements and new product launches. Underlying growth was 3.1%, offset by a 1.5% foreign exchange headwind and one fewer trading day in Q1 2025 compared to Q1 2024.
- Segment Performance:
- Orthopaedics: Underlying growth of 3.2%. Growth in US Hip and Knee Implants and Trauma & Extremities offset by declines in China. Other Reconstruction saw significant growth (46.6% underlying) driven by the CORI Surgical System.
- Sports Medicine & ENT: Underlying growth of 2.4%. Strong performance in Established Markets and Joint Repair offset by headwinds in China.
- Advanced Wound Management: Underlying growth of 3.8%. Driven by foams and Negative Pressure Wound Therapy (NPWT), offset by expected volatility in SANTYL.
- Geographic Performance: Established Markets grew 4.1% underlying (US: 3.6%, Other: 5.0%). Emerging Markets declined 1.7% underlying, primarily due to China headwinds. Excluding China, Emerging Markets grew 14.7% underlying.
Guidance, Outlook, and Risks
- Full Year 2025 Guidance: Unchanged.
- Revenue: Underlying growth expected around 5.0% (reported growth 5.4%).
- Margins: Trading profit margin expected to expand to between 19.0% and 20.0%, with stronger performance in the second half.
- Management Commentary: CEO Deepak Nath highlighted a "good start" to the year, driven by the "12-Point Plan" operational improvements. Key platforms (CORI, EVOS, REGENETEN, NPWT) delivered double-digit growth. Management believes the peak impact of China headwinds has passed.
- Risks and Contingencies:
- Tariffs: Uncertainty remains regarding tariff imposition. The company expects a net impact of $15–$20 million in 2025 based on announced measures and is leveraging its global manufacturing network to mitigate costs.
- China VBP: Continued headwinds from Volume-Based Procurement (VBP) in China, with additional impacts expected in the second half of 2025 for Arthroscopic Enabling Technologies.
- Regulatory: Pending FDA clearance for the TESSA Spatial Surgery System.
Investor Verification Checklist
- Verify the sustainability of the 3.1% underlying revenue growth given the -150bps FX headwind and one fewer trading day.
- Monitor the actual impact of China VBP on Sports Medicine and Orthopaedics in Q2 and Q3 2025.
- Assess the effectiveness of tariff mitigation strategies given the dynamic political environment and the projected $15–$20 million cost.
- Track the adoption rates of new product launches (CORI, CATALYSTEM, REGENETEN, ALLEVYN Ag+ SURGICAL) to ensure they meet the "multi-year growth runway" expectations.
- Confirm the trajectory of trading profit margin expansion toward the 19.0%–20.0% full-year target, particularly in the second half.